Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids

Durán‐Lobato, Matilde; Martín-Banderas, Lucía; Gonçalves, Lídia; Fernández‐Arévalo, M.; Almeida, António J.

doi:10.1007/s11051-015-2875-y

Cited by 57 publications

(41 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, whereas the authors that tried to encapsulate distinct cannabinoids in polymer nanoparticles only achieved encapsulation efficiencies around 70% [15,16,21], those studies that utilized lipid-based carriers exhibited values above 90% [17,22]. This comparison has been corroborated by Durán-Lobato et al [23]. Unlike these authors, we utilized a low-energy method to prepare monodisperse lipid carriers in smaller sizes.…”

Section: Resultsmentioning

confidence: 52%

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Aparicio-Blanco

Sebastián

Benoı̂t

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

The therapeutic potential of cannabinoids has been truly constrained heretofore due to their strong psychoactive effects and their high lipophilicity. In this context, precisely due to the lack of psychoactive properties, cannabidiol (CBD), the second major component of Cannabis sativa, arises as the phytocannabinoid with the most auspicious therapeutic potential. Hence, the incorporation of CBD in lipid nanocapsules (LNCs) will contribute to overcome the dosing problems associated with cannabinoids.Herein, we have prepared LNCs decorated and loaded with CBD for glioma therapy and screened in vitro their critical parameters. On the one hand, we have encapsulated CBD into the oily core of LNCs to test their in vitro efficacy as extendedrelease carriers against the human glioblastoma cell line U373MG. The in vitro antitumor effect was highly dependent on the size of LNCs due to its pivotal role in the extent of CBD release. Effectively, a comparison between two differently-sized LNCs (namely, 20-nm and 50-nm sized carriers) showed that the smaller LNCs reduced by 3.0-fold the IC 50 value of their 50-nm sized counterparts. On the other hand, to explore the potential of this phytocannabinoid to target any of the cannabinoid receptors overexpressed in glioma cells, we decorated the LNCs with CBD. This functionalization strategy enhanced the in vitro glioma targeting by 3.4-fold in comparison with their equally-sized undecorated counterparts. Lastly, the combination of CBD-loading with CBD-functionalization further reduced the IC 50 values. Hence, the potential of these two strategies of CBD incorporation into LNCs deserves subsequent in vivo evaluation.

show abstract

Section: Resultsmentioning

confidence: 52%

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Aparicio-Blanco

Sebastián

Benoı̂t

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…Notably, there was no burst effect, and constant drug release was achieved for F1. 47 This was due to several reasons. Firstly, the physical barrier of CS that coated PLGA NPs limited the diffusion/erosion process of drug from NPs.…”

Section: Discussionmentioning

confidence: 99%

<p>Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium</p>

Arafa¹,

Girgis²,

El-Dahan³

2020

IJN

View full text Add to dashboard Cite

Background: Atorvastatin calcium (AT) is an ocular anti-inflammatory with limited bioavailability when taken orally due to its low solubility in low pH and extensive first-pass effect. To overcome these problems, AT was entrapped in polymeric nanoparticles (NPs) to improve surface properties and sustained release, in addition to achieving site-specific action. Methods: AT was entrapped in chitosan (CS)-coated polylactic-co-glycolic acid (PLGA) NPs to form AT-PLGA-CS-NPs (F1). F1 and free AT were embedded in thermosensitive Pluronic ® 127-hydroxypropyl methylcellulose (HPMC) to form thermosensitive gels (F2) and (F3) while F4 is AT suspension in water. F1 was assessed for size, surface charge, polydispersity index (PDI), and morphology. F2 and F3 were examined for gelation temperature, gel strength, pH, and viscosity. In vitro release of the four formulations was also investigated. The ocular irritancy and anti-inflammatory efficacy of formulations against prostaglandin E 1-(PGE 1) induced ocular inflammation in rabbits were investigated by counting the polymorphonuclear leukocytes (PMNs) and protein migrated in tears. Results: Oval F1 of 80.0-190.0±21.6 nm exhibited a PDI of 0.331 and zeta potential of 17.4 ±5.62 mV with a positive surface charge. F2 and F3 gelation temperatures were 35.17±0.22°C and 36.93±0.31°C, viscosity 12,243±0.64 and 9759±0.22 cP, gel strength 15.56±0.6 and 12.45 ±0.1 s, and pHs of 7.4±0.02 and 7.4±0.1, respectively. In vitro release of F1, F2, F3, and F4 were 48.21±0.31, 26.48±0.5, 84.76±0.11, and 100% after 24 hrs, respectively. All formulations were non-irritant. F2 significantly inhibited lid closure up to 3 h, PMN counts and proteins in tear fluids up to 5 h compared to other formulations. Conclusion: AT-PLGA-CS-NP thermosensitive gels proved to be successful ocular antiinflammatory drug delivery systems.

show abstract

“…The results showed that for long-term circulation without any surface modification, the 100 nm nanoparticles worked best because they could escape the liver metabolism (107). This and several other studies suggest that PLGA is a promising candidate for enhancing therapeutic delivery into the CNS (108)(109)(110)(111)(112)(113)(114)(115)(116)(117)(118)(119)(120). However, PLGA degrades by bulk erosion, which can lead to premature exposure of the therapeutic to a degradative environment.…”

mentioning

confidence: 77%

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

et al. 2018

View full text Add to dashboard Cite

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components at the blood-brain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD.

show abstract

Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids

Cited by 57 publications

References 57 publications

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

<p>Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium</p>

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

Contact Info

Product

Resources

About